UNSPSC 51413210: Vardenafil dihydrochloride

This classification denotes the dihydrochloride form of a cgmp phosphodiesterase inhibitor with the molecular formula C23H32N6O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UCE6F4125H, chemically known as 2-(2-ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3h-imidazo(5,1-f)(1,2,4)triazin-4-one but more generally known as vardenafil, which bears US NIH Compound Identifier 110634.

UNSPSC 51413210 Vardenafil dihydrochloride, a Commodity code, encompasses pharmaceutical procurement by state and local governments, though the recent opportunities block shows limited direct alignment with this specific active pharmaceutical ingredient. State and local purchasing departments and health agencies do acquire medications for emergency response, public health programs, and employee benefit administration, but the three most recent opportunities in the record target broader pharmaceutical categories rather than vardenafil specifically. The City of Tampa's Fire Rescue procurement solicits advanced life support medications including epinephrine, adenosine, labetalol, and diltiazem for emergency medical services. The Texas Health and Human Services Commission is conducting exploratory work on direct-to-manufacturer prescription programs to support its pharmacy benefit objectives. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing master agreements for generic multi-source pharmaceuticals and OTC products across participating state and local entities. Issuing bodies range from municipal fire departments to state health agencies and multistate purchasing cooperatives, with MMCAP representing a significant vehicle for coordinated procurement across multiple jurisdictions.

Recent activity shows geographic spread across Texas, Minnesota (with participating states including Oregon), and Florida, reflecting both regional and multistate cooperative purchasing approaches. The City of Tampa's sealed-bid solicitation 26P00188 for Advanced Life Support Medications closed April 8, 2026, with an estimated contract value of $40,000 and a SLBE sheltered market designation; the contract term runs one year with options for two additional one-year renewals. The Minnesota MMCAP RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products had proposals due March 26, 2026, with contract effectiveness targeted for July 1, 2026, and a two-year initial term. The Texas HHS Commission's RFI (HHS0017013) on direct-to-manufacturer prescriptions closed April 3, 2026, as an exploratory information-gathering phase preceding a formal RFP. The source provides no recent opportunities specifically naming vardenafil; the code's current activity signal reflects broader pharmaceutical procurement patterns rather than demand for this particular compound.